Phase II study of intravenous 6-thioguanine in patients with advanced carcinoma of the pancreas.
In a phase II study, 32 patients with advanced pancreatic carcinoma were treated with intravenous 6-thioguanine. A 30-min infusion of 55 mg/m2 (starting dose) was administered once a day for 5 consecutive days, the course being repeated every 5 weeks. A median of two courses (range, 1-10) was administered. Among the 32 patients, 30 having measurable cancer and optimum follow-up were fully assessable for response. One patient achieved a partial response of extensive liver metastases (12+ months), and another patient had a transient minor response (5 weeks). Cancer in 27 of 30 assessable patients progressed during intravenous 6-thioguanine treatment. Myelosuppression, although frequent, was mild to moderate at these doses and did not result in significant morbidity. Nonhematologic toxicities were also mild. Our data suggest that intravenous 6-thioguanine given at this schedule is ineffective in previously untreated patients with advanced carcinoma of the pancreas.
Ajani
J A
JA
Department of Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston.
Pazdur
R
R
Winn
R J
RJ
Abbruzzese
J L
JL
Levin
B
B
Belt
R
R
Young
J
J
Patt
Y Z
YZ
Krakoff
I H
IH
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D013866:Thioguanine / Q000008:administration & dosage* / Q000009:adverse effects
D013866:Thioguanine